Siddiqi, Shan H. http://orcid.org/0000-0002-0967-9289
Philip, Noah S. http://orcid.org/0000-0002-4889-8775
Palm, Stephan T. http://orcid.org/0009-0000-8345-5470
Carreon, David M.
Arulpragasam, Amanda R.
Barredo, Jennifer
Bouchard, Heather http://orcid.org/0000-0002-3646-6334
Ferguson, Michael A.
Grafman, Jordan H. http://orcid.org/0000-0001-8645-4457
Morey, Rajendra A.
Fox, Michael D. http://orcid.org/0000-0001-8848-6399
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (K23MH121657, R21MH126271, R01MH136248, U01 MH123427, P20 GM130452, R01MH113929, R21MH126271)
Brain and Behavior Research Foundation
U.S. Department of Veterans Affairs (I50 RX002864)
U.S. Department of Health & Human Services | National Institutes of Health (R56AG069086, R01MH115949, R01AG060987)
Article History
Received: 6 March 2024
Accepted: 26 August 2024
First Online: 24 September 2024
Competing interests
: There are no personal financial conflicts of interest related to the present results. S.H.S. is an owner of intellectual property involving the use of individualized resting-state network mapping to target TMS, which was filed in 2016, has yielded no royalties and does not cover the present work. S.H.S. is also a scientific consultant for Magnus Medical, received investigator-initiated research funding from Neuronetics (2019) and Brainsway (2022), received speaking fees from Brainsway (2021) and Otsuka (for PsychU.org, 2021), and is a shareholder in Brainsway (publicly traded) and Magnus Medical (not publicly traded). M.D.F. is a scientific consultant for Magnus Medical. M.D.F. also owns independent intellectual property involving the use of functional connectivity to target TMS for depression, which was filed in 2013, has yielded no royalties and does not cover the present work. N.S.P. received clinical trial support (through VA contracts) from Wave Neuroscience and Neurolief, serves on the scientific advisory board for Pulvinar Neuro and serves as a consultant for Motif Neurotech. The other authors declare no competing interests.